Ginkgo Bioworks Holdings Inc. (NYSE: DNA) is -21.89% lower on its value in year-to-date trading and has touched a low of $1.19 and a high of $4.91 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DNA stock was last observed hovering at around $1.33 in the last trading session, with the day’s loss setting it -0.01% off its average median price target of $3.70 for the next 12 months. It is also 89.0% off the consensus price target high of $12.00 offered by 9 analysts, but current levels are 24.57% higher than the price target low of $1.75 for the same period.
Currently trading at $1.32, the stock is -9.90% and -20.53% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 16.99 million and changing -0.75% at the moment leaves the stock -45.53% off its SMA200. DNA registered -54.64% loss for a year compared to 6-month loss of -57.00%.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
The stock witnessed a -23.70% gain in the last 1 month and extending the period to 3 months gives it a -24.14%, and is 5.60% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.58% over the week and 8.60% over the month.
Ginkgo Bioworks Holdings Inc. (DNA) has around 641 employees, a market worth around $2.44B and $477.70M in sales. Distance from 52-week low is 10.92% and -73.12% from its 52-week high. The company has generated returns on investments over the last 12 months (-119.60%).
Ginkgo Bioworks Holdings Inc. (DNA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Ginkgo Bioworks Holdings Inc. (DNA) is a “Overweight”. 9 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 1 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Ginkgo Bioworks Holdings Inc. is expected to release its quarterly report on 05/15/2023.The EPS is expected to grow by 72.80% this year
Ginkgo Bioworks Holdings Inc. (DNA) Top Institutional Holders
The shares outstanding are 1.63B, and float is at 1.17B with Short Float at 12.50%.
Ginkgo Bioworks Holdings Inc. (DNA) Insider Activity
A total of 458 insider transactions have happened at Ginkgo Bioworks Holdings Inc. (DNA) in the last six months, with sales accounting for 427 and purchases happening 31 times. The most recent transaction is an insider sale by Dmytruk Mark E., the company’s. SEC filings show that Dmytruk Mark E. sold 29,762 shares of the company’s common stock on Mar 15 at a price of $1.31 per share for a total of $39107.0. Following the sale, the insider now owns 0.53 million shares.
Ginkgo Bioworks Holdings Inc. disclosed in a document filed with the SEC on Mar 14 that Kelly Jason R () sold a total of 300,000 shares of the company’s common stock. The trade occurred on Mar 14 and was made at $1.33 per share for $0.4 million. Following the transaction, the insider now directly holds 12.29 million shares of the DNA stock.
Still, SEC filings show that on Mar 14, Canton Barry (10% Owner) disposed off 75,300 shares at an average price of $1.33 for $0.1 million. The insider now directly holds 13,918,194 shares of Ginkgo Bioworks Holdings Inc. (DNA).
